United Therapeutics revealed unexpected positive Phase 3 results for nebulized Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF), meeting primary and key secondary endpoints including improvements in forced vital capacity (FVC) over 52 weeks. The safety profile was consistent and the benefits extended across patient subgroups. The data set the stage for a supplemental NDA filing. Analysts estimate the IPF market opportunity at over $4 billion. The advance follows disappointing runs by competitors and highlights innovation in inhaled therapies for fibrotic lung disease.